These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 36571995)

  • 1. Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y
    Yuan Y; Yan Z; Lao Q; Jiang N; Wu S; Lu Q; Han J; Zhao S
    Eur J Med Chem; 2023 Feb; 247():115036. PubMed ID: 36571995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
    Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
    Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of Xenopus GLP-1-Based Long-Acting Dual GLP-1/Y
    Yang Q; Tang W; Sun L; Yan Z; Tang C; Yuan Y; Zhou H; Zhou F; Zhou S; Wu Q; Song P; Fang T; Xu R; Han J; Jiang N
    J Med Chem; 2022 Oct; 65(20):14201-14220. PubMed ID: 36214844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.
    Zimmermann T; Thomas L; Baader-Pagler T; Haebel P; Simon E; Reindl W; Bajrami B; Rist W; Uphues I; Drucker DJ; Klein H; Santhanam R; Hamprecht D; Neubauer H; Augustin R
    Mol Metab; 2022 Dec; 66():101633. PubMed ID: 36356832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists.
    Zhang X; Cai Y; Yao Z; Chi H; Li Y; Shi J; Zhou Z; Sun L
    Peptides; 2023 Mar; 161():170948. PubMed ID: 36646385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xenopus GLP-1-based glycopeptides as dual glucagon-like peptide 1 receptor/glucagon receptor agonists with improved in vivo stability for treating diabetes and obesity.
    Li Q; Yang Q; Han J; Liu X; Fu J; Yin J
    Chin J Nat Med; 2022 Nov; 20(11):863-872. PubMed ID: 36427920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
    Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
    Thomas L; Martel E; Rist W; Uphues I; Hamprecht D; Neubauer H; Augustin R
    Diabetes Obes Metab; 2024 Jun; 26(6):2368-2378. PubMed ID: 38560764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys.
    Elvert R; Bossart M; Herling AW; Weiss T; Zhang B; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Keil S; Lorenz M; Lorenz K; Riz M; Hennerici W; Larsen PJ
    Endocrinology; 2018 Aug; 159(8):3105-3119. PubMed ID: 29992313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists.
    Jiang N; Jing L; Li Q; Su S; Yang Q; Zhou F; Chen X; Han J; Tang C; Tang W
    Eur J Med Chem; 2021 Feb; 212():113118. PubMed ID: 33422984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus.
    Wang W; Wen X; Duan W; Wang X; Chen Y; Dong J; Yang Z; Fang J; Zhou Z; Yao G; Fang Y; Huang Y
    J Endocrinol Invest; 2020 May; 43(5):653-662. PubMed ID: 31786794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
    Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
    Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering a potent and long-acting GLP-1/Y
    Xu J; Wang S; Wu H; Chen D; Han J; Lin Q
    Peptides; 2023 Nov; 169():171073. PubMed ID: 37536423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors.
    Vishnoi S; Bhattacharya S; Walsh EM; Okoh GI; Thompson D
    J Chem Inf Model; 2023 Aug; 63(15):4934-4947. PubMed ID: 37523325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of site-directed mutagenesis of GLP-1 and glucagon receptors on signal transduction activated by dual and triple agonists.
    Darbalaei S; Chang RL; Zhou QT; Chen Y; Dai AT; Wang MW; Yang DH
    Acta Pharmacol Sin; 2023 Feb; 44(2):421-433. PubMed ID: 35953646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration.
    Kopp KO; Li Y; Glotfelty EJ; Tweedie D; Greig NH
    Biomolecules; 2024 Jul; 14(7):. PubMed ID: 39062586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
    Pocai A; Carrington PE; Adams JR; Wright M; Eiermann G; Zhu L; Du X; Petrov A; Lassman ME; Jiang G; Liu F; Miller C; Tota LM; Zhou G; Zhang X; Sountis MM; Santoprete A; Capito' E; Chicchi GG; Thornberry N; Bianchi E; Pessi A; Marsh DJ; SinhaRoy R
    Diabetes; 2009 Oct; 58(10):2258-66. PubMed ID: 19602537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity.
    Winther JB; Holst JJ
    Diabetes Obes Metab; 2024 Sep; 26(9):3501-3512. PubMed ID: 38853300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.
    Al-Zamel N; Al-Sabah S; Luqmani Y; Adi L; Chacko S; Schneider TD; Krasel C
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel chimeric multi-agonist peptide (GEP44) reduces energy intake and body weight in male and female diet-induced obese mice in a glucagon-like peptide-1 receptor-dependent manner.
    Blevins JE; Honeycutt MK; Slattery JD; Goldberg M; Rambousek JR; Tsui E; Dodson AD; Shelton KA; Salemeh TS; Elfers CT; Chichura KS; Ashlaw EF; Zraika S; Doyle RP; Roth CL
    Front Endocrinol (Lausanne); 2024; 15():1432928. PubMed ID: 39104812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.